胰腺癌与糖尿病的关系

南昇辰; 石乔; 陈辰; 王卫星

doi:10.3969/j.issn.1001-5256.2022.12.039

胰腺癌与糖尿病的关系

DOI: 10.3969/j.issn.1001-5256.2022.12.039

南昇辰^a,
石乔^a,
陈辰^b,
王卫星^a, , ,

a.
武汉大学人民医院胰腺外科, 武汉 430060
b.
武汉大学人民医院普外科, 武汉 430060

基金项目:

国家自然科学基金 (82170651);

国家自然科学基金 (81870442)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：南昇辰负责收集资料，整合资料，撰写论文；石乔负责拟定写作思路，指导文章撰写；陈辰负责修改文章；王卫星设计文章思路，审核文章并最后定稿。

详细信息

通信作者:
王卫星, sate.llite@163.com

计量
- 文章访问数: 1775
- HTML全文浏览量: 1112
- PDF下载量: 71
- 被引次数: 0
出版历程
- 收稿日期: 2020-07-30
- 录用日期: 2020-08-31
- 出版日期: 2022-12-20

Association between pancreatic cancer and diabetes

a.
Department of Pancreatic Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China
b.
Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China

Research funding:

National Natural Science Foundation of China (82170651);

National Natural Science Foundation of China (81870442)

More Information

Corresponding author: WANG Weixing, sate.llite@163.com (ORCID: 0000-0002-3854-0083)

摘要

摘要: 胰腺癌是一类高度恶性的消化系统肿瘤，总体5年生存率不足10%。近年来，大量研究表明胰腺癌与糖尿病呈双向关系，糖尿病既是胰腺癌的高危因素之一，也是胰腺癌引起的一种副肿瘤现象。2型糖尿病患者的高血糖和高胰岛素血症是发生胰腺癌的危险因素；相反胰腺癌细胞通过自分泌或旁分泌引起胰岛β细胞功能受损，导致胰源性糖尿病的发生。本文对流行病学、发病机制及胰腺癌与糖尿病的双向关系作一综述，为临床提供参考。
- 胰腺肿瘤 /
- 糖尿病 /
- 病理过程
Abstract: Pancreatic cancer is a type of highly malignant digestive system tumor, with a 5-year overall survival rate of < 10%. In recent years, a large number of studies have shown that there is a two-way relationship between pancreatic cancer and diabetes; diabetes is not only one of the high-risk factors for pancreatic cancer, but also a paraneoplastic phenomenon caused by pancreatic cancer. Hyperglycemia and hyperinsulinemia in patients with type 2 diabetes are risk factors for pancreatic cancer, and on the contrary, pancreatic cancer cells cause the dysfunction of pancreatic β cells through autocrine or paracrine pathways and thus lead to the onset of pancreatic diabetes. This article reviews the epidemiology and pathogenesis of pancreatic cancer and the two-way relationship between pancreatic cancer and diabetes, so as to provide a reference for clinical practice.
- Pancreatic Neoplasms /
- Diabetes Mellitus /
- Pathologic Processes

HTML全文

参考文献(51)

[1]	SIEGEL RL, MILLER KD, FUCHS HE, et al. Cancer statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. DOI: 10.3322/caac.21654.
[2]	ROY A, SAHOO J, KAMALANATHAN S, et al. Diabetes and pancreatic cancer: Exploring the two-way traffic[J]. World J Gastroenterol, 2021, 27(30): 4939-4962. DOI: 10.3748/wjg.v27.i30.4939.
[3]	SHARMA A, SMYRK TC, LEVY MJ, et al. Fasting blood glucose levels provide estimate of duration and progression of pancreatic cancer before diagnosis[J]. Gastroenterology, 2018, 155(2): 490-500. DOI: 10.1053/j.gastro.2018.04.025.
[4]	SAH RP, NAGPAL SJ, MUKHOPADHYAY D, et al. New insights into pancreatic cancer-induced paraneoplastic diabetes[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(7): 423-433. DOI: 10.1038/nrgastro.2013.49.
[5]	KLEEFF J, COSTELLO E, JACKSON R, et al. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer[J]. Br J Cancer, 2016, 115(7): 887-894. DOI: 10.1038/bjc.2016.277.
[6]	BITTERMAN DS, WINTER KA, HONG TS, et al. Impact of diabetes and insulin use on prognosis in patients with resected pancreatic cancer: An ancillary analysis of NRG oncology RTOG 9704[J]. Int J Radiat Oncol Biol Phys, 2021, 109(1): 201-211. DOI: 10.1016/j.ijrobp.2020.08.042.
[7]	KOO DH, HAN KD, PARK CY. The incremental risk of pancreatic cancer according to fasting glucose levels: Nationwide population-based cohort study[J]. J Clin Endocrinol Metab, 2019, 104(10): 4594-4599. DOI: 10.1210/jc.2019-00033.
[8]	LIAO WC, TU YK, WU MS, et al. Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis[J]. BMJ, 2015, 350: g7371. DOI: 10.1136/bmj.g7371.
[9]	SONG S, WANG B, ZHANG X, et al. Long-term diabetes mellitus is associated with an increased risk of pancreatic cancer: A meta-analysis[J]. PLoS One, 2015, 10(7): e0134321. DOI: 10.1371/journal.pone.0134321.
[10]	ANDERSEN DK, KORC M, PETERSEN GM, et al. Diabetes, pancreatogenic diabetes, and pancreatic cancer[J]. Diabetes, 2017, 66(5): 1103-1110. DOI: 10.2337/db16-1477.
[11]	RAGHAVAN SR, BALLEHANINNA UK, CHAMBERLAIN RS. The impact of perioperative blood glucose levels on pancreatic cancer prognosis and surgical outcomes: an evidence-based review[J]. Pancreas, 2013, 42(8): 1210-1217. DOI: 10.1097/MPA.0b013e3182a6db8e.
[12]	PANG Y, KARTSONAKI C, GUO Y, et al. Diabetes, plasma glucose and incidence of pancreatic cancer: A prospective study of 0.5 million Chinese adults and a meta-analysis of 22 cohort studies[J]. Int J Cancer, 2017, 140(8): 1781-1788. DOI: 10.1002/ijc.30599.
[13]	WOLPIN BM, BAO Y, QIAN ZR, et al. Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer[J]. J Natl Cancer Inst, 2013, 105(14): 1027-1035. DOI: 10.1093/jnci/djt123.
[14]	TURATI F, ROSSI M, MATTIOLI V, et al. Diabetes risk reduction diet and the risk of pancreatic cancer[J]. Eur J Nutr, 2022, 61(1): 309-316. DOI: 10.1007/s00394-021-02646-5.
[15]	SHARMA A, KANDLAKUNTA H, NAGPAL S, et al. Model to determine risk of pancreatic cancer in patients with new-onset diabetes[J]. Gastroenterology, 2018, 155(3): 730-739. DOI: 10.1053/j.gastro.2018.05.023.
[16]	MOLINA-MONTES E, COSCIA C, GÓMEZ-RUBIO P, et al. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses[J]. Gut, 2021, 70(2): 319-329. DOI: 10.1136/gutjnl-2019-319990.
[17]	PANNALA R, LEIRNESS JB, BAMLET WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus[J]. Gastroenterology, 2008, 134(4): 981-987. DOI: 10.1053/j.gastro.2008.01.039.
[18]	HART PA, BAICHOO E, BI Y, et al. Pancreatic polypeptide response to a mixed meal is blunted in pancreatic head cancer associated with diabetes mellitus[J]. Pancreatology, 2015, 15(2): 162-166. DOI: 10.1016/j.pan.2015.02.006.
[19]	BAO J, LIU D, SUN J, et al. Pancreatic cancer-associated diabetes mellitus is characterized by reduced β-cell secretory capacity, rather than insulin resistance[J]. Diabetes Res Clin Pract, 2022, 185: 109223. DOI: 10.1016/j.diabres.2022.109223.
[20]	ROHRMANN S, GROTE VA, BECKER S, et al. Concentrations of IGF-I and IGFBP-3 and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition[J]. Br J Cancer, 2012, 106(5): 1004-1010. DOI: 10.1038/bjc.2012.19.
[21]	TRAJKOVIC- ARSIC M, KALIDERIS E, SIVEKE JT. The role of insulin and IGF system in pancreatic cancer[J]. J Mol Endocrinol, 2013, 50(3): R67-R74. DOI: 10.1530/JME-12-0259.
[22]	HOPKINS BD, PAULI C, DU X, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors[J]. Nature, 2018, 560(7719): 499-503. DOI: 10.1038/s41586-018-0343-4.
[23]	HUA F, LI K, YU JJ, et al. TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations[J]. Nat Commun, 2015, 6: 7951. DOI: 10.1038/ncomms8951.
[24]	ZHOU C, QIAN W, LI J, et al. High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer[J]. J Exp Clin Cancer Res, 2019, 38(1): 302. DOI: 10.1186/s13046-019-1288-7.
[25]	RAHN S, ZIMMERMANN V, VIOL F, et al. Diabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelial cells[J]. Cancer Lett, 2018, 415: 129-150. DOI: 10.1016/j.canlet.2017.12.004.
[26]	LI W, ZHANG L, CHEN X, et al. Hyperglycemia promotes the epithelial-mesenchymal transition of pancreatic cancer via hydrogen peroxide[J]. Oxid Med Cell Longev, 2016, 2016: 5190314. DOI: 10.1155/2016/5190314.
[27]	KISS K, BAGHY K, SPISÁK S, et al. Chronic hyperglycemia induces trans-differentiation of human pancreatic stellate cells and enhances the malignant molecular communication with human pancreatic cancer cells[J]. PLoS One, 2015, 10(5): e0128059. DOI: 10.1371/journal.pone.0128059.
[28]	HAN L, MA Q, LI J, et al. High glucose promotes pancreatic cancer cell proliferation via the induction of EGF expression and transactivation of EGFR[J]. PLoS One, 2011, 6(11): e27074. DOI: 10.1371/journal.pone.0027074.
[29]	DUAN Q, LI H, GAO C, et al. High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway[J]. J Exp Clin Cancer Res, 2019, 38(1): 192. DOI: 10.1186/s13046-019-1209-9.
[30]	WU D, HU D, CHEN H, et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer[J]. Nature, 2018, 559(7715): 637-641. DOI: 10.1038/s41586-018-0350-5.
[31]	INCIO J, LIU H, SUBOJ P, et al. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy[J]. Cancer Discov, 2016, 6(8): 852-869. DOI: 10.1158/2159-8290.CD-15-1177.
[32]	INCIO J, TAM J, RAHBARI NN, et al. PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity[J]. Clin Cancer Res, 2016, 22(12): 2993-3004. DOI: 10.1158/1078-0432.CCR-15-1839.
[33]	WHATCOTT CJ, DIEP CH, JIANG P, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer[J]. Clin Cancer Res, 2015, 21(15): 3561-3568. DOI: 10.1158/1078-0432.CCR-14-1051.
[34]	SCHMITZ J, DITTMAR IC, BROCKMANN JD, et al. Defense against reactive carbonyl species involves at least three subcellular compartments where individual components of the system respond to cellular sugar status[J]. Plant Cell, 2017, 29(12): 3234-3254. DOI: 10.1105/tpc.17.00258.
[35]	YAO D, BROWNLEE M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands[J]. Diabetes, 2010, 59(1): 249-255. DOI: 10.2337/db09-0801.
[36]	DINORCIA J, LEE MK, MOROZIEWICZ DN, et al. RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer[J]. J Gastrointest Surg, 2012, 16(1): 104-112; discussion 112. DOI: 10.1007/s11605-011-1754-9.
[37]	SWAMI P, THIYAGARAJAN S, VIDGER A, et al. RAGE up-regulation differently affects cell proliferation and migration in pancreatic cancer cells[J]. Int J Mol Sci, 2020, 21(20): 7723. DOI: 10.3390/ijms21207723.
[38]	LECLERC E, VETTER SW. The role of S100 proteins and their receptor RAGE in pancreatic cancer[J]. Biochim Biophys Acta, 2015, 1852(12): 2706-2711. DOI: 10.1016/j.bbadis.2015.09.022.
[39]	MENINI S, IACOBINI C, DE LATOULIERE L, et al. The advanced glycation end-product NE-carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes-associated risk and its prevention[J]. J Pathol, 2018, 245(2): 197-208. DOI: 10.1002/path.5072.
[40]	KANG R, HOU W, ZHANG Q, et al. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer[J]. Cell Death Dis, 2014, 5: e1480. DOI: 10.1038/cddis.2014.445.
[41]	MENINI S, IACOBINI C, DE LATOULIERE L, et al. Diabetes promotes invasive pancreatic cancer by increasing systemic and tumour carbonyl stress in Kras^G12D/+ mice[J]. J Exp Clin Cancer Res, 2020, 39(1): 152. DOI: 10.1186/s13046-020-01665-0.
[42]	AGGARWAL G, RAMACHANDRAN V, JAVEED N, et al. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice[J]. Gastroenterology, 2012, 143(6): 1510-1517. DOI: 10.1053/j.gastro.2012.08.044.
[43]	PANG W, YAO W, DAI X, et al. Pancreatic cancer-derived exosomal microRNA-19a induces β-cell dysfunction by targeting ADCY1 and EPAC2[J]. Int J Biol Sci, 2021, 17(13): 3622-3633. DOI: 10.7150/ijbs.56271.
[44]	TAVANO F, FONTANA A, MAZZA T, et al. Early-Onset diabetes as risk factor for pancreatic cancer: mirna expression profiling in plasma uncovers a role for mir-20b-5p, mir-29a, and mir-18a-5p in diabetes of recent diagnosis[J]. Front Oncol, 2020, 10: 1567. DOI: 10.3389/fonc.2020.01567.
[45]	SU J, PANG W, ZHANG A, et al. Exosomal miR-19a decreases insulin production by targeting Neurod1 in pancreatic cancer associated diabetes[J]. Mol Biol Rep, 2022, 49(3): 1711-1720. DOI: 10.1007/s11033-021-06980-z.
[46]	ŠKRHA J, BUŠEK P, UHROVÁ J, et al. Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss[J]. Pancreatology, 2017, 17(1): 89-94. DOI: 10.1016/j.pan.2016.12.004.
[47]	ZHANG Y, HUANG S, LI P, et al. Pancreatic cancer-derived exosomes suppress the production of GIP and GLP-1 from STC-1 cells in vitro by down-regulating the PCSK1/3[J]. Cancer Lett, 2018, 431: 190-200. DOI: 10.1016/j.canlet.2018.05.027.
[48]	JAVEED N, SAGAR G, DUTTA SK, et al. Pancreatic cancer-derived exosomes cause paraneoplastic β-cell dysfunction[J]. Clin Cancer Res, 2015, 21(7): 1722-1733. DOI: 10.1158/1078-0432.CCR-14-2022.
[49]	WANG L, ZHANG B, ZHENG W, et al. Exosomes derived from pancreatic cancer cells induce insulin resistance in C2C12 myotube cells through the PI3K/Akt/FoxO1 pathway[J]. Sci Rep, 2017, 7(1): 5384. DOI: 10.1038/s41598-017-05541-4.
[50]	American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021[J]. Diabetes Care, 2021, 44(Suppl 1): S15-S33. DOI: 10.2337/dc21-S002.
[51]	CARRERAS-TORRES R, JOHANSSON M, GABORIEAU V, et al. The role of obesity, type 2 diabetes, and metabolic factors in pancreatic cancer: a Mendelian randomization study[J]. J Natl Cancer Inst, 2017, 109(9): djx012. DOI: 10.1093/jnci/djx012.